NCT01259375View on ClinicalTrials.gov

Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Amrubicin

Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously

Trial Locations (2)

84112

Huntsman Cancer Institute, Salt Lake City

90403

Santa Monica, Santa Monica

All Listed Sponsors
lead

University of Utah

OTHER

NCT01259375 - Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter